Crossmark

Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial

Crossref DOI link: https://doi.org/10.1186/s40164-025-00687-8

Published Online: 2025-07-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhao, Ke

Lin, Ren

Fan, Zhiping

Li, Zhen

Chen, Xiaoyong

Xuan, Li

Huang, Fen

Xu, Na

Wu, Xiuli

Chen, Shaohua

Sun, Jing

Zhang, Xi

Weng, Jianyu

Li, Yonghua

Li, Yuhua

Lin, Dongjun

Nie, Danian

Wang, Shunqing

Xu, Xiaojun

Zhang, Xiaohui

Li, Yangqiu

Xiang, AP

Wang, Yu

Liu, Qifa
Funding

Funding for this research was provided by:

GuangDong Basic and Applied Basic Research Foundation (2025A1515012748)

President Foundation of Nanfang Hospital, Southern Medical University (2023A036)

National Natural Science Foundation of China (82470214)

National Key Research and Development Program of China (2023YFC2508905, 2022YFA11050003)

Major Program of the National Natural Science Foundation of China (82293634)
License Information

Text and Data Mining valid from 2025-07-09

Version of Record valid from 2025-07-09
More Information

Article History

Received: 22 April 2025

Accepted: 30 June 2025

First Online: 9 July 2025

Declarations

:

: This study was conducted in compliance with the Declaration of Helsinki principles. All procedures involving human subjects were approved by the Nanfang Hospital of Southern Medical University Review Board.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below